射血分数保留心力衰竭中的线粒体功能障碍
该综述聚焦射血分数保留心力衰竭(HFpEF)的运动不耐受,认为其由心脏及外周动脉和骨骼肌异常共同导致,线粒体异常可显著影响氧利用。文章回顾线粒体生物学、人体线粒体功能评估方法及线粒体功能障碍参与HFpEF病理生理的证据,并讨论以线粒体为治疗靶点的早期临床试验设计要点及正在进行的相关试验。
要点
- HFpEF运动不耐受由心脏与外周(动脉和骨骼肌)异常共同导致。
- 线粒体异常可显著损害氧利用,参与HFpEF运动不耐受。
- 线粒体功能是HFpEF的潜在治疗靶点,需关注早期试验设计。
核心结论
- 线粒体功能障碍参与HFpEF病理生理,并可能作为改善症状的治疗靶点。
研究设计与样本
- 综述,总结线粒体生物学、人体线粒体功能评估方法及HFpEF相关证据。
主要发现
- HFpEF运动不耐受由心脏及外周动脉和骨骼肌异常共同导致。
- 线粒体异常可显著导致氧利用受损和运动不耐受。
- 已有证据支持线粒体功能障碍在HFpEF病理生理中的作用。
临床怎么用
- 可关注线粒体功能作为HFpEF症状改善的干预靶点。
- 设计靶向线粒体的早期临床试验时需考虑关键设计要点。
- 需了解正在进行的HFpEF线粒体药物试验。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Heart failure with preserved ejection fraction (HFpEF) is a complex syndrome with an increasingly recognized heterogeneity in pathophysiology. Exercise intolerance is the hallmark of HFpEF and appears to be caused by both cardiac and peripheral abnormalities in the arterial tree and skeletal muscle. Mitochondrial abnormalities can significantly contribute to impaired oxygen utilization and the resulting exercise intolerance in HFpEF. We review key aspects of the complex biology of this organelle, the clinical relevance of mitochondrial function, the methods that are currently available to assess mitochondrial function in humans, and the evidence supporting a role for mitochondrial dysfunction in the pathophysiology of HFpEF. We also discuss the role of mitochondrial function as a therapeutic target, some key considerations for the design of early-phase clinical trials using agents that specifically target mitochondrial function to improve symptoms in patients with HFpEF, and ongoing trials with mitochondrial agents in HFpEF.
引用
- Kumar AA, Kelly DP, Chirinos JA, et al. Mitochondrial Dysfunction in Heart Failure With Preserved Ejection Fraction. Circulation. 2019. PMID: 30856000. doi:10.1161/CIRCULATIONAHA.118.036259
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。